瘦素水平和骨反应:探索超重患者与正常体重II类患者的功能治疗疗效
Ece Karaer1, Serife Sahin2, Kubra Bozali3
1Private Practice, Istanbul, Turkey.
概括
唾液勒丁水平与II类恶性闭塞患者的骨和牙反应相关. 超重患者的瘦素含量较高,成熟时间较早,治疗结果不同,影响了青少年的治疗计划.
科学领域:
- ортодонтика和牙科人类学
- 内分泌学和新陈代谢学
背景情况:
- 骨II类缺陷是一个常见的正牙问题.
- 功能疗法是成长期患者的标准治疗方法.
- 像勒素这样的代谢因素在正治疗反应中的作用尚未完全理解.
研究的目的:
- 研究在正常体重与超重的II类缺陷病患者接受功能治疗时的唾液勒丁水平和骨/牙结局之间的相关性.
- 评估体重对治疗反应的影响.
主要方法:
- 对32名II类第1部门坏闭症患者的前性队列研究 (正常体重与超重).
- 在MP3cap生长阶段使用双块设备进行治疗.
- 在多个时间点评估横向脑度X射线,BMI和唾液瘦素水平 (ELISA).
主要成果:
- 超重患者的唾液叶素含量较高,骨成熟时间较早.
- 在超重患者中观察到更大的切肢运动和下长度增加.
- 莱普与上变化和软组织凸度正相关,与后面面部高度和下切肢倾斜度负相关.
结论:
- 体重显著影响治疗时间和II类缺陷纠正的结果.
- 唾液勒丁水平可以作为预测治疗反应的生物标志物.
- 考虑患者的体重对于有效的青少年正牙治疗计划至关重要.
相关概念视频
Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Insulin: Dosing Regimen and Adverse Effects
673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K


